Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 25% ± 8% | |
retinal rod cell | 8 studies | 39% ± 12% | |
oligodendrocyte precursor cell | 7 studies | 41% ± 19% | |
endothelial cell of lymphatic vessel | 6 studies | 17% ± 2% | |
retinal cone cell | 6 studies | 46% ± 16% | |
retinal bipolar neuron | 5 studies | 30% ± 10% | |
epithelial cell | 5 studies | 26% ± 7% | |
amacrine cell | 5 studies | 24% ± 7% | |
oligodendrocyte | 5 studies | 31% ± 5% | |
retinal pigment epithelial cell | 4 studies | 30% ± 14% | |
fibroblast | 4 studies | 17% ± 1% | |
neuron | 4 studies | 38% ± 13% | |
GABAergic neuron | 3 studies | 37% ± 14% | |
CD4-positive, alpha-beta T cell | 3 studies | 21% ± 5% | |
glomerular endothelial cell | 3 studies | 17% ± 0% | |
podocyte | 3 studies | 29% ± 10% | |
microglial cell | 3 studies | 19% ± 2% | |
retina horizontal cell | 3 studies | 30% ± 7% | |
Mueller cell | 3 studies | 24% ± 4% | |
OFF-bipolar cell | 3 studies | 35% ± 13% | |
ON-bipolar cell | 3 studies | 33% ± 11% | |
rod bipolar cell | 3 studies | 39% ± 12% | |
glutamatergic neuron | 3 studies | 45% ± 19% | |
interneuron | 3 studies | 40% ± 19% | |
astrocyte | 3 studies | 28% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 4643.66 | 2642 / 2642 | 100% | 71.12 | 705 / 705 |
prostate | 100% | 4186.07 | 245 / 245 | 100% | 44.45 | 500 / 502 |
breast | 100% | 4786.13 | 459 / 459 | 99% | 48.82 | 1110 / 1118 |
ovary | 100% | 6839.09 | 180 / 180 | 99% | 32.91 | 426 / 430 |
thymus | 100% | 4600.92 | 653 / 653 | 99% | 42.26 | 599 / 605 |
esophagus | 100% | 3154.16 | 1444 / 1445 | 99% | 30.02 | 181 / 183 |
lung | 99% | 3084.56 | 571 / 578 | 99% | 32.99 | 1149 / 1155 |
bladder | 100% | 3289.33 | 21 / 21 | 98% | 35.50 | 495 / 504 |
kidney | 100% | 4185.43 | 89 / 89 | 98% | 39.17 | 884 / 901 |
adrenal gland | 100% | 4441.73 | 258 / 258 | 98% | 35.27 | 225 / 230 |
pancreas | 99% | 2359.78 | 326 / 328 | 98% | 30.14 | 175 / 178 |
stomach | 100% | 2709.50 | 359 / 359 | 98% | 37.41 | 279 / 286 |
intestine | 100% | 3776.62 | 965 / 966 | 97% | 35.08 | 513 / 527 |
uterus | 100% | 5747.17 | 170 / 170 | 97% | 32.02 | 446 / 459 |
skin | 100% | 4669.11 | 1809 / 1809 | 94% | 59.20 | 444 / 472 |
liver | 100% | 2585.41 | 226 / 226 | 92% | 22.08 | 374 / 406 |
muscle | 100% | 3169.47 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4956.56 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 16.92 | 1 / 1 |
adipose | 100% | 4718.32 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3123.77 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 3683.06 | 854 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 21.19 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 24.50 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 94% | 38.85 | 75 / 80 |
peripheral blood | 53% | 843.99 | 495 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0036211 | Biological process | protein modification process |
GO_0005737 | Cellular component | cytoplasm |
GO_0004719 | Molecular function | protein-L-isoaspartate (D-aspartate) O-methyltransferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | PCMTD2 |
Protein name | Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 (Protein-L-isoaspartate O-methyltransferase domain-containing protein 2) PCMTD2 protein Protein-L-isoaspartate O-methyltransferase domain-containing protein 2 Protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2 |
Synonyms | C20orf36 |
Description | FUNCTION: May act as a substrate recognition component of an ECS (Elongin BC-CUL5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. May bind to the methyltransferase cofactor S-adenosylmethionine (AdoMet) via the N-terminal AdoMet binding motif, but probably does not display methyltransferase activity. . |
Accessions | ENST00000610196.1 V9GZ41 ENST00000628846.1 I6L9C7 ENST00000631244.2 [Q9NV79-2] ENST00000609372.1 ENST00000610074.1 ENST00000629502.1 ENST00000308824.11 [Q9NV79-1] Q6PIM4 V9GYG6 ENST00000629544.1 ENST00000615818.3 [Q9NV79-1] F8W9F3 Q9NV79 ENST00000609764.1 ENST00000369758.8 [Q9NV79-2] V9GYL1 A0A0G2JR02 ENST00000618274.4 ENST00000628717.1 A0A0G2JM70 V9GYZ4 ENST00000609818.1 V9GYZ7 ENST00000299468.12 ENST00000627852.1 ENST00000608844.1 ENST00000627415.2 [Q9NV79-1] |